The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 14, 2021

Filed:

Jul. 23, 2015
Applicants:

Imperial College Innovations Limited;

Institut Pasteur, Paris, FR;

Université Paris-saclay, Saint Aubin, FR;

Inventors:

Screaton Gavin, London, GB;

Juthathip Mongkolsapaya, London, GB;

Alexander Rouvinski, Paris, FR;

Pablo Guardado-Calvo, Paris, FR;

Giovanna Barba-Spaeth, Paris, FR;

Stéphane Duquerroy, Paris, FR;

Marie-Christine Vaney, Paris, FR;

Felix Augusto Rey, Paris, FR;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/005 (2006.01); A61K 39/12 (2006.01); C07K 16/10 (2006.01); C07K 14/18 (2006.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); A61K 39/12 (2013.01); A61K 47/6841 (2017.08); C07K 14/1825 (2013.01); C07K 16/1081 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/76 (2013.01); C12N 2770/24122 (2013.01); C12N 2770/24134 (2013.01); Y02A 50/30 (2018.01);
Abstract

A Dengue virus Envelope Dimer Epitope (EDE) wherein the EDE: c) spans the polypeptides of a Dengue virus Envelope polypeptide dimer; and/or d) is presented on a dimer of Envelope proteins; and/or c) is formed from consecutive or non-consecutive residues of the envelope polypeptide dimer, wherein the dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides, from any one or two of DENV-1, DENV-2, DENV-3 and DENV-4. The EDE may be a stabilized recombinant dengue virus envelope glycoprotein E ectodomain (sE) dimer, wherein the dimer is: covalently stabilized with at least one disulphide inter-chain bond between the two sE monomers, and/or covalently stabilized with at least one sulfhydryl-reactive crosslinker between the two sE monomers, and/or covalently stabilized by linking the two sE monomers through modified sugars; and/or, covalently stabilised by being formed as a single polypeptide chain, optionally with a linker region, optionally a Glycine Serine rich linker region, separating the sE sequences, and/or non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain 1 (D1)/domain 3 (D3) linker of each monomer. A compound, for example an antibody or antibody fragment that can neutralise more than one Dengue virus serotype, for example an antibody that can bind to an EDE of the invention.


Find Patent Forward Citations

Loading…